Follicular lymphoma and the immune system: From pathogenesis to antibody therapy

Blood

Volumn 119, Issue 16, 2012, Pages 3659-3667

  Stevenson, Freda K ^a   Stevenson, George T ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIIDIOTYPIC ANTIBODY; CD20 ANTIBODY; CD20 ANTIGEN; CELL SURFACE IMMUNOGLOBULIN; FC RECEPTOR; GLYCAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LECTIN; MANNOSE; OBINUTUZUMAB; OFATUMUMAB; RHESUS D ANTIBODY; RITUXIMAB;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIGENIC MODULATION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE INFLAMMATION; B LYMPHOCYTE; CANCER ANTIBODY THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG DOSE ESCALATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; EFFECTOR CELL; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOMODULATION; INFLAMMATION; LEUKEMIA; LYMPHOMAGENESIS; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SOMATIC HYPERMUTATION; SOMATIC MUTATION; STROMA CELL; THROMBOCYTOPENIC PURPURA;

EID: 84860346868     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-367730     Document Type: Review

References (110)

1. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20(40):5580-5594. (Pubitemid 32928099)
2. Roulland S, Faroudi M, Mamessier E, Sungalee S, Salles G, Nadel B. Early steps of follicular lymphoma pathogenesis. Adv Immunol. 2011;111:1-46.
3. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118(11):2976-2984.
4. Ruminy P, Jardin F, Picquenot JM, et al. S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells. Blood. 2008;112(5):1951-1959.
5. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol. 1997;15(4):1587-1594. (Pubitemid 27167397)
6. Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):147-163.
7. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14): 1827-1834.
8. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
9. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by in-ducible gene targeting results in rapid cell death. Cell. 1997;90(6):1073-1083. (Pubitemid 27408521)
10. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65(6):1349-1363. (Pubitemid 15057941)
11. Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood. 2002; 99(7):2562-2568. (Pubitemid 34525446)
12. Radcliffe CM, Arnold JN, Suter DM, et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem. 2007;282(10):7405-7415. (Pubitemid 47096594)
13. Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol. 1983;130(2):970-973. (Pubitemid 13186337)
14. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17): 1209-1215.
15. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171-1177. (Pubitemid 29474422)
16. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20): 2787-2794.
17. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457-2466. (Pubitemid 24317376)
18. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
19. Vuist WM, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood. 1994;83(4):899-906.
20. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115-123.
21. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107-114.
22. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol. 1998;16:421-432. (Pubitemid 28183371)
23. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest. 2002;110(12):1823-1830. (Pubitemid 36076489)
24. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma. Blood. 1997; 90(6):2188-2195. (Pubitemid 27392702)
25. Mottok A, Renne C, Seifert M, et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood. 2009;114(20): 4503-4506.
26. Carlotti E, Wrench D, Matthews J, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood. 2009;113(15):3553-3557.
27. Schmitz R, Renne C, Rosenquist R, et al. Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas. Leukemia. 2005;19(8):1452-1458. (Pubitemid 41136341)
28. Aarts WM, Bende RJ, Steenbergen EJ, et al. Variable heavy chain gene analysis of follicular lymphomas: correlation between heavy chain isotype expression and somatic mutation load. Blood. 2000;95(9):2922-2929. (Pubitemid 30235904)
29. Zhu D, Ottensmeier CH, Du MQ, McCarthy H, Stevenson FK. Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. Br J Haematol. 2003;120(2):217-222. (Pubitemid 36194169)
30. McCann KJ, Ottensmeier CH, Callard A, et al. Remarkable selective glycosylation of the immu-noglobulin variable region in follicular lymphoma. Mol Immunol. 2008;45(6):1567-1572. (Pubitemid 351221145)
31. Coelho V, Krysov S, Ghaemmaghami AM, et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci U S A. 2010;107(43):18587-18592.
32. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol. 2008;8(11):874-887.
33. Ubelhart R, Bach MP, Eschbach C, Wossning T, Reth M, Jumaa H. N-linked glycosylation selectively regulates autonomous precursor BCR function. Nat Immunol. 2010;11(8):759-765.
34. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481-504. (Pubitemid 27169290)
35. Irish JM, Myklebust JH, Alizadeh AA, et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A. 2010;107(29):12747-12754.
36. Allavena P, Chieppa M, Bianchi G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol. 2010;2010:547179.
37. Calvo KR, Dabir B, Kovach A, et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood. 2008;112(9):3818-3826.
38. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169. (Pubitemid 39507628)
39. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17): 2902-2913.
40. Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009; 27(9):1470-1476.
41. Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lym-phomawith anti-idiotype antibodies. N Engl J Med. 1985;312(26):1658-1665. (Pubitemid 15068572)
42. Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Microbiol Immunol. 2011;344:193-210.
43. George AJ, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol. 1987;138(2): 628-634. (Pubitemid 17002231)
44. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22(23): 4717-4724.
45. Hsueh RC, Hammill AM, Lee JA, Uhr JW, Scheuermann RH. Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes. BMC Immunol. 2002;3: 16.
46. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev. 2010;237(1):72-89.
47. Savelyeva N, Shipton M, Suchacki A, Babbage G, Stevenson FK. High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen. Blood. 2011;118(3):650-659.
48. Pejchal R, Doores KJ, Walker LM, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIVglycan shield. Science. 2011; 334(6059):1097-1103.
49. Hersey P. New look at antiserum therapy of leukaemia. Nat New Biol. 1973;244(131):22-24.
50. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3(1):21-26.
51. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4): 443-446. (Pubitemid 30208162)
52. Angelini DF, Borsellino G, Poupot M, et al. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004; 104(6):1801-1807. (Pubitemid 39202290)
53. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199(12):1659-1669. (Pubitemid 38821999)
54. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203(3):743-753.
55. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005; 174(7):4389-4399. (Pubitemid 40396022)
56. van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer: on the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest. 1992;67(2): 166-174.
57. Hubert P, Heitzmann A, Viel S, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 2011;71(15):5134-5143.
58. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIagene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
59. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21): 3940-3947. (Pubitemid 46606207)
60. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001;98(5):1352-1357.
61. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111(3):1456-1463. (Pubitemid 351213433)
62. Old LJ, Boyse EA. Antigenic properties of experimental leukemias: I. Serological studies in vitro with spontaneous and radiation-induced leukemias. J Natl Cancer Inst. 1963;31:977-995.
63. Stackpole CW, Jacobson JB, Lardis MP. Antigenic modulation in vitro: I. Fate of thymus-leukemia (TL) antigen-antibody complexes following modulation of TL antigenicity from the surfaces of mouse leukemia cells and thymocytes. J Exp Med. 1974;140(4):939-953.
64. Glennie M, Stevenson FK, Stevenson GT, Virji M. Cross-linking of lymphocytic surface immunoglobulin inhibits its production via a cyclic nucleotide mechanism. Nature. 1979;281(5729):305-307. (Pubitemid 10225339)
65. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003;4(9):815. (Pubitemid 37098646)
66. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176(4):2600-2609. (Pubitemid 43201712)
67. Riond J, Elhmouzi J, Hudrisier D, Gairin JE. Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter by CD8(+) T cells. Scand J Immunol. 2007;66(4):441-450. (Pubitemid 47394565)
68. Zhou G, Ding ZC, Fu J, Levitsky HI. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response. J Immunol. 2011;186(4):2148- 2155.
69. Schreiner GF, Unanue ER. Calcium-sensitive modulation of Ig capping: evidence supporting a cytoplasmic control of ligand receptor complexes. J Exp Med. 1976;143(1):15-31.
70. Gordon J, Robinson DS, Stevenson GT. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis: I. Characterization with syngeneic and xenogeneic complements. Immunology. 1981;42(1): 7-12. (Pubitemid 11034616)
71. Lane AC, Foroozan S, Glennie MJ, Kowalski-Saunders P, Stevenson GT. Enhanced modulation of antibodies coating guinea pig leukemic cells in vitro and in vivo: the role of Fc gamma R expressing cells. J Immunol. 1991;146(7):2461-2468.
72. Glennie MJ, Stevenson GT. Univalent antibodies kill tumour cells in vitro and in vivo. Nature. 1982; 295(5851):712-714. (Pubitemid 12116153)
73. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal antiidiotype antibody. N EnglJ Med. 1982;306(9): 517-522. (Pubitemid 12175745)
74. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood. 1998;92(4):1184-1190. (Pubitemid 28369031)
75. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989;49(17):4906-4912. (Pubitemid 19213646)
76. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in pa-tients with chronic lymphocytic leukemia. Blood. 2003;102(10):3514-3520. (Pubitemid 37419939)
77. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5):3280-3288. (Pubitemid 38263720)
78. Taylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol. 2010; 47(2):124-132.
79. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15(10):3266-3274. (Pubitemid 27419340)
80. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191-5201.
81. Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118(9):2530-2540.
82. Callanan MB, Le Baccon P, Mossuz P, et al. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc Natl Acad Sci U S A. 2000;97(1):309-314. (Pubitemid 30055827)
83. Chen W, Palanisamy N, Schmidt H, et al. Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene. 2001; 20(52):7686-7693. (Pubitemid 33111868)
84. Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009; 113(16):3809-3812.
85. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9(9):995-1001. (Pubitemid 28496709)
86. Nakamura RM, Spiegelberg HL, Lee S, Weigle WO. Relationship between molecular size and intra-and extravascular distribution of protein antigens. J Immunol. 1968;100(2):376-383.
87. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228-1231.
88. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins: understanding properties and mechanisms. Clin Exp Immunol. 2009; 158(suppl 1):2-13.
89. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev. 2010;236:265-275.
90. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475(7354):110-113.
91. Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferongamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007; 26(1):67-78. (Pubitemid 46127754)
92. Wymann S, Ghielmetti M, Schaub A, et al. Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens. Mol Immunol. 2008;45(9):2621-2628.
93. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98(4): 1095-1099.
94. Cheung E, Liebman HA. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics. 2009;3:57-62.
95. Cooper N, Heddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol. 2004;124(4):511-518. (Pubitemid 38230598)
96. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood. 2005;105(4):1546-1548. (Pubitemid 40223672)
97. Stevenson GT. Is antibody therapy of tumor compromised by infusion-related reactions? A case for inhibiting the activity of cyclooxygenase-2. Leuk Res. 2005;29(3):239-246. (Pubitemid 40127048)
98. Samuelsson A, Towers TL, Ravetch JV. Antiinflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001; 291(5503):484-486. (Pubitemid 32097072)
99. Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood. 2011;117(11):2993-3001.
100. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371. (Pubitemid 43939148)
101. Wierda WG, Kipps TJ, Durig J, et al. Chemoim-munotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117(24):6450-6458.
102. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22): 4393-4402.
103. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11): 4005-4010.
104. Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 2007;67(18): 8882-8890. (Pubitemid 47437465)
105. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002; 277(30):26733-26740. (Pubitemid 34951677)
106. Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. J Immunol Methods. 2001; 248(1):1-6. (Pubitemid 32167020)
107. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. 2000; 406(6793):267-273. (Pubitemid 30604397)
108. Leong WS, Thomas KA, Chan CH, Stevenson GT. A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcgamma receptors II and III. Mol Immunol. 2011; 48(5):760-768.
109. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372(6504):379-383. (Pubitemid 24363442)
110. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164(8):4178-4184. (Pubitemid 30215076)